Patents by Inventor Leah Mitchell

Leah Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200172870
    Abstract: The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppressive effects obtained by cells expressing increased PD-L1 and/or IDO-1.
    Type: Application
    Filed: December 2, 2019
    Publication date: June 4, 2020
    Inventors: David Robbins, Betsy Rezner, Leah Mitchell, Lisa Guerrettaz, Philippe Alessandro Parone, Robert Steven Tacke, Kevin Lai, Bahram Valamehr
  • Publication number: 20190119635
    Abstract: The present disclosure relates to molecular biology, cell biology and immunology. Specifically, the present disclosure provides compositions and methods for modulating an isolated population of T lymphocytes to improve the therapeutic potential thereof.
    Type: Application
    Filed: May 4, 2016
    Publication date: April 25, 2019
    Inventors: David Robbins, Betsy Denise Rezner, Lisa Guerrettaz, Leah Mitchell
  • Patent number: 10206983
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 19, 2019
    Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda Guth, Leah Mitchell
  • Publication number: 20180112180
    Abstract: The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppressive effects obtained by cells expressing increased PD-L1 and/or IDO-1.
    Type: Application
    Filed: January 26, 2016
    Publication date: April 26, 2018
    Inventors: David Robbins, Betsy Rezner, Leah Mitchell, Lisa Guerrettaz, Philippe Alessandro Parone, Robert Steven Tacke, Kevin Lai, Bahram Valamehr
  • Publication number: 20170348400
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Application
    Filed: January 6, 2017
    Publication date: December 7, 2017
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda Guth, Leah Mitchell
  • Patent number: 9539314
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: January 10, 2017
    Assignee: Colorado State University Research Foundation
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda M. Guth, Leah Mitchell
  • Publication number: 20160287686
    Abstract: Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and/or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and/or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.
    Type: Application
    Filed: March 17, 2016
    Publication date: October 6, 2016
    Inventors: Steven W. Dow, Angela J. Henderson, Leah Mitchell
  • Patent number: 9320735
    Abstract: Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and/or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and/or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: April 26, 2016
    Assignee: Colorado State University Research Foundation
    Inventors: Steven W. Dow, Angela J Henderson, Leah Mitchell
  • Publication number: 20150182608
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Application
    Filed: January 29, 2015
    Publication date: July 2, 2015
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda M. Guth, Leah Mitchell
  • Patent number: 8975290
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: March 10, 2015
    Assignee: Colorado State University Research Foundation
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda M. Guth, Leah Mitchell
  • Publication number: 20140248315
    Abstract: Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.
    Type: Application
    Filed: March 3, 2014
    Publication date: September 4, 2014
    Applicant: Colorado State University Research Foundation
    Inventors: Steven W. Dow, Daniel P. Regan, Amanda M. Guth, Leah Mitchell
  • Publication number: 20120156280
    Abstract: Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and/or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and/or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.
    Type: Application
    Filed: June 22, 2011
    Publication date: June 21, 2012
    Applicant: Colorado State University Research Foundation
    Inventors: Steven W. Dow, Angela J. Henderson, Leah Mitchell